GH/IGF-1 axis modulation Several Sikiric studies (2010-2020) reported indirect modulation of the GH-IGF-1 axis by BPC-157, with moderate induction of GH receptor expression in scar tissue
The Fat Loss Mechanism The proposed fat loss mechanism of 5-amino-1MQ operates through several interrelated effects: NNMT inhibition preserves SAM and NAD+ pools Increased NAD+ supports sirtuin activity and mitochondrial function Reduced lipogenesis adipocyte fatty acid synthesis is decreased Enhanced adipocyte metabolism improved adipose tissue function Selective effect on adipocytes relative sparing of other tissues Preclinical studies have shown that 5-amino-1MQ treatment in mice produces: Reduced body fat mass Improved insulin sensitivity Preserved lean mass Favorable effects on liver fat in diet-induced obesity models The Human Clinical Trials Picture As of 2026, human clinical trial activity for 5-amino-1MQ is emerging but not yet mature
A deficiency in these nutrients has been linked to mental health symptoms such as anxiety and depression, which are not solely explained by insulin resistance
Plus/Max add NAD+ tiers for deeper energy + clarity recovery patterns
Designed for multi-dose reconstitution in research and clinical applications
Worst locations: The door (temperature swings every time you open the fridge), the back wall of the fridge (risk of freezing if too close to the cooling element), and the crisper drawer (humidity concerns)
